All In Biotech

Drug Trial Radar · NCT06702618

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Evaluation of the Efficacy and Safety of TQB3616 Capsules Combined With Hormonal Therapy in a Phase II Clinical Trial for Cyclin-dependent Kinases 4 and 6(CDK4/6)Inhibitor-Resistant, Hormone Receptor(HR)-Positive, Human Epidermal Growth Factor Receptor 2(HER2)-Negative Recurrent/Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

33

Planned (sponsor's estimate)

Start

Feb 20, 2025

Primary completion

Jun 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Nov 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of the Efficacy and Safety of TQB3616 Capsules Combined with Hormonal Therapy in a Phase II Clinical Trial for Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor-Resistant, HR-Positive, HER2-Negative Recurrent/Metastatic Breast Cancer.

Conditions

  • Breast Cancer

Interventions

  • TQB3616 capsule+Fulvestrant InjectionDrug

    TQB3616 capsule is a CDK2/4/6 inhibitor and Fulvestrant injection is an anti-estrogen medication, and its pharmacological mechanism mainly exerts its therapeutic effect by inhibiting the action of aromatase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: Baseline up to 12 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affilliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China

  • Jiangmen Central Hospital

    Jiangmen, Guangdong, China

  • Xingtai People's Hospital

    Xingtai, Hebei, China

  • Harbin Medical University Cancer Hostipal

    Harbin, Heilongjiang, China

  • Luohe Central Hospital

    Luohe, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China

  • Hai'an People's Hospital

    Nantong, Jiangsu, China

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China

  • Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)

    Jinan, Shandong, China

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi’an, Shanxi, China

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.